eIF4E binding peptides

Abstract

The present invention relates to modified eIF4G1 peptides, uses thereof and pharmaceutical compositions comprising the modified eIF4G1 peptides.

What is claimed is: 
     
       1. A modified eukaryotic translation initiation factor 4 gamma 1 (eIF4G1) peptide derived from the human eIF4G1 protein with the amino acid sequence SEQ ID NO. 8, wherein the peptide has been modified to stabilize the α-helix wherein the peptide comprises the amino acid sequence KKRYDREFLL*FQF (SEQ ID NO: 10), wherein * represents a non-natural amino acid. 
     
     
       2. The modified eIF4G1 peptide of  claim 1 , wherein the modified eIF4G1 peptide comprises a sequence selected from the group consisting of Linker-KKRYDREFLL*FQF(SEQ ID NO: 10)-NH2 and KKRYDREFLL*FQF(SEQ ID NO: 10)-NH2. 
     
     
       3. The modified eIF4G1 peptide of  claim 1 , wherein the modified peptide comprises a protection group. 
     
     
       4. The modified eIF4G1 peptide of  claim 3 , wherein the protection group is an acyl or acetyl group. 
     
     
       5. The modified eIF4G1 peptide of  claim 1 , wherein the modified peptide comprises capping groups at the N-terminus and/or the C-terminus. 
     
     
       6. The modified eIF4G1 peptide of  claim 1 , wherein the non-natural amino acid is a cycloalkane derivative. 
     
     
       7. The modified eIF4G1 peptide of  claim 6 , wherein the cycloalkane derivative is selected from the group consisting of 1-aminocyclopentanoic acid, 1-aminocyclohexanoic acid, β-cyclohexylalanine, an α-(1-carboxycyclopentyl)glycine, 1-aminocyclopropanoic acid, 1-amino cyclobutanoic acid and aminomethylcyclohexanoic acid. 
     
     
       8. The modified eIF4G1 peptide of  claim 1 , wherein the modified eIF4G1 peptide further comprises an N-terminus which is modified. 
     
     
       9. The modified eIF4G1 peptide of  claim 1 , wherein the modified eIF4G1 peptide further comprises a C-terminus which is modified.